The SGLT2 inhibitors, as a class, lead to similar treatment benefits at comparable clinical doses, although there are some discrepancies between them, particularly when dapagliflozin (Farxiga; ...
Enrollment insights in the synchronous mRCC population: An update from the ongoing ADAPT* phase 3 study experience. Background: Pazopanib is an oral, selective, multikinase inhibitor of VEGF receptors ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results